p110-delta inhibitors treat and prevent autoimmunity while sparing the ability to mount an immune response to exogenous immunogens

US11701361B2 · kind B2 · utility

Assignees

• NATIONAL INSTITUTES OF HEALTH (NCH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT NIH DIVISION OF EXTRAMURAL INVENTIONS AND TECHNOLOGY RESOURCES (DEITR) · US
• The Regents of the University of Colorado · US

Inventors

• John C. Cambier · Denver, US
• Elizabeth Franks · Denver, US

Key dates

• Filing date: Jan 7, 2019
• Grant date: Jul 18, 2023
• Expiry date: Mar 11, 2039

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P37/02
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Methods of using a phosphoinositide 3-kinase p110-delta inhibitor to treat, delay the onset, or slow the progression of an autoimmune disease or disorder in a subject, without suppressing the subject's B cell responses to exogenous antigens or rendering the subject immunocompromised, as well as pharmaceutical compositions containing phosphoinositide 3-kinase p110-delta inhibitors in amounts suitable for convenient and accurate administration within these therapeutic methods.